Search clinical trials for: radioimmunotherapy

Total 79 results

University Hospital Muenster
Isotope Technologies Munich (ITM) Oncologics; Helmholtz Zentrum München Deutsches...

Recruiting

Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment (RIT in GBM)

Glioblastom WHO Grade 4

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Y-mAbs Therapeutics

Recruiting

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Sarcoma | SCLC | Malignant Melanoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Y-mAbs Therapeutics

Terminated

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Neuroblastoma | Leptomeningeal Metastases | CNS Metastases

United States, Denmark, Japan, Spain
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
Nordic Nanovector

Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell Lymphoma

Spain, United Kingdom, Italy, United States, Germany
Nordic Nanovector
ICON Clinical Research

Completed

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (LYMRIT-37-07)

Follicular Lymphoma | Non Hodgkin Lymphoma | Relapsed Follicular Lymphoma

Czechia, Norway
Y-mAbs Therapeutics

Terminated

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Peritoneal Cancer

United States
University of Nebraska

Completed

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

Lymphoma

United States
Y-mAbs Therapeutics

Terminated

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Medulloblastoma, Childhood

United States, Spain, United Kingdom, Denmark, Netherlands
Biogen

Completed

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Low-Grade

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Actinium Pharmaceuticals

Active, not recruiting

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | AML | Acute Myelogenous Leukemia | Bone Marrow Transplant | Myelogenous Leukemia, Acute | Myeloid Leukemia, Acute | Leukemia, Acute Myelogenous | Leukemia, Acute Myeloid

United States, Canada
BioNTech Research & Development, Inc.

Terminated

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Pancreatic Carcinoma | Tumors That Express CA 19-9

United States
Nordic Nanovector
ICON Clinical Research

Active, not recruiting

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
Nantes University Hospital

Terminated

Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer (RITCOLON)

Metastatic Colorectal Cancer

France
Y-mAbs Therapeutics

Withdrawn

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Solid Tumor, Adult | Leptomeningeal Metastasis

United States, United Kingdom
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (HNO-2)

Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditions

Austria
Great Ormond Street Hospital for Children NHS Foundation...

Completed

Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia

Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloblastic Leukemia

United Kingdom
Weill Medical College of Cornell University

Completed

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

Prostate Cancer

United States
Bayer

Completed

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Sweden, United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin Lymphoma

United States
Sheba Medical Center
City of Hope Medical Center; Amsterdam UMC, location VUmc; University of Göttingen

Completed

Zevalin-beam for Aggressive Lymphoma

Non-Hodgkin's Lymphoma

United States, Netherlands, Germany, Israel
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Brain and Central Nervous System Tumors

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Lymphoma, Mantle-Cell
The Christie NHS Foundation Trust
Bayer

Completed

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (FIZZ)

Follicular Lymphoma

United Kingdom, France
University Hospital Southampton NHS Foundation...
Royal Free and University College Medical School

Completed

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

Lymphoma | Myeloma | Acute Leukaemia | Chronic Leukaemia

United Kingdom
Nordic Nanovector

Withdrawn

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Non-Hodgkin Lymphoma

Germany
Weill Medical College of Cornell University
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Completed

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

Non-Hodgkin's Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
GlaxoSmithKline

Completed

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL (SPINOZA)

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Weill Medical College of Cornell University
Gilead Sciences

Terminated

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Follicular Lymphoma

United States
National Center for Tumor Diseases, Heidelberg
Heidelberg University; iOMEDICO AG

Unknown

Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades (SUPPORT)

Pain

Germany
GlaxoSmithKline

Completed

Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Refractory Anemia With Excess... and other conditions

United States
GlaxoSmithKline

Completed

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Lymphoma, Non-Hodgkin
Duke University
GlaxoSmithKline

Completed

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Lymphoma, B-Cell

United States
GlaxoSmithKline

Completed

A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin

United States, France, United Kingdom
GlaxoSmithKline

Completed

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (RIT-II-001)

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
University of Pennsylvania
GlaxoSmithKline

Completed

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

B-cell Lymphoma | Non-Hodgkin's Lymphoma

United States
University of Michigan
National Institutes of Health (NIH)

Completed

Imaging Based Dosimetry for Individualized Internal Emitter Therapy

Non-Hodgkin's Lymphoma

United States
Radboud University Medical Center
Gilead Sciences

Completed

Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging

Colonic Neoplasms

Netherlands
Lund University Hospital
Bayer

Completed

High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma (HITT)

B-cell Lymphoma

Sweden

Search clinical trials for: radioimmunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations